News

Eli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.
A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...
Can Novo Nordisk’s New CEO Stop Rivals From Taking Over the Anti-Obesity Market?
Danish leader will face a challenging landscape among competitors ...
Just The News5h
Trump administration considering pilot program to cover weight loss drugs under Medicare, Medicaid
The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...
Trump’s Weight-Loss Experiment Could Aid Lilly, Novo. Cost Is Still a Problem.
The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.
Why Novo Nordisk Stock Bumped Higher on Friday
Both Novo Nordisk's Wegovy and rival Eli Lilly's Zepbound are essentially versions of predecessor diabetes drugs. Some ...
Weight-loss patients taking Zepbound forced to switch to Wegovy after drop in coverage
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
The Economist2d
Indian firms aim to gorge on weight-loss drugs
Indian pharma is hoping to cash in. Generic firms, such as Biocon, are already offering weight-loss drugs, such as cheaper ...
Novo Nordisk A/S (NVO) Could Lose To Eli Lilly, Warns Jim Cramer
We recently published 10 Stocks That Jim Cramer Talked About. Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer ...